News & Analysis as of

Private Equity Regulatory Requirements Acquisitions

Cozen O'Connor

Pennsylvania Legislature Revives Bill Scrutinizing Health Care Transactions

Cozen O'Connor on

Throughout the country, state governments have been introducing bills which grant state authorities the ability to closely scrutinize health care transactions – specifically, with an eye toward those involving private equity....more

MoFo Life Sciences

Key Developments in MedTech M&A: Momentum Despite Macroeconomic Uncertainty

MoFo Life Sciences on

2024 was a challenging year for M&A activity in the medical technology (“MedTech”) industry. Although some sectors experienced a rebound in deal volume, MedTech dealmakers were disproportionately affected by a difficult...more

A&O Shearman

Creative deal structures help life sciences innovators ride out the macro storm

A&O Shearman on

Globally, market volatility has eroded confidence and subdued M&A activity. A “wait and see” approach is the prevailing sentiment for many market participants; it is difficult to convince boards to advance deals while...more

A&O Shearman

M&A in a period of turbulence

A&O Shearman on

Macroeconomic volatility, shifting trade policies, and regulatory change continue to shape the dealmaking landscape. Here we explore the challenges and opportunities for buyers and sellers navigating uncertain markets. The...more

Ropes & Gray LLP

California’s Office of Health Care Affordability (“OHCA”) Initiates First Cost and Market Impact Review (“CMIR”)

Ropes & Gray LLP on

On June 6, 2025, the California Office of Health Care Affordability (“OHCA”) issued its first determination to conduct a Cost and Market Impact Review (“CMIR”) under its health care oversight law. This CMIR will involve...more

McDermott Will & Emery

CA Senate amends AB 1415 to reinsert MSO reporting requirements

On June 27, 2025, the California Senate amended Assembly Bill (AB) 1415 to add back in a reporting requirement for management services organizations (MSOs) undergoing a sale of a material amount of assets or change of...more

White & Case LLP

Two years of the EU Foreign Subsidies Regulation – what dealmakers need to know

White & Case LLP on

Two years ago, the FSR arrived as the new kid on the block in Brussels. Today, it is one of the EU's sharpest enforcement tools, and one that is only gaining prominence as geopolitical tensions reshape global investment and...more

DLA Piper

A Growing State of Oversight: How States are Continuing to Reshape (and restrict) Healthcare Transactions and Private Equity...

DLA Piper on

State governments are increasingly introducing new laws regulating healthcare transactions in an effort to thwart the level of influence that private equity firms and other corporate investors have on healthcare providers. To...more

Skadden, Arps, Slate, Meagher & Flom LLP

Europe’s Sharpened Focus on Defense Creates M&A and Investment Opportunities

Key Points - - The war in Ukraine has prompted a historic surge in European defense spending. - Governments in the EU and U.K. are stressing the need for innovation. They are increasingly turning to investment in small...more

White & Case LLP

Beating the hackers: US cybersecurity dealmaking hits back against rising attacks - Policymakers have renewed their focus on...

White & Case LLP on

The persistence and evolution of cybercrime across the US is reshaping M&A in the cybersecurity sector. Driven by escalating threats, increasing costs and liability to businesses, and a growing and more defined regulatory...more

White & Case LLP

DOJ Declines to Prosecute Private Equity Firm after Post-Acquisition Voluntary Self-Disclosure of Sanctions and Export Control...

White & Case LLP on

In its first application of the policy on voluntary self-disclosures (“VSDs”) in connection with mergers and acquisitions (“M&A”), on June 16, 2025, the US Department of Justice’s (“DOJ”) National Security Division (“NSD”)...more

ArentFox Schiff

Private Equity Investment in Health Care Providers and Technology – 2025 Midyear Outlook

ArentFox Schiff on

As of mid-2025, private equity (PE) investors remain intensely interested in health care services and technology companies despite higher borrowing costs, heightened regulatory scrutiny, and an increasingly complex state...more

Vedder Price

New Oregon Law Imposes Significant Corporate Practice of Medicine Restrictions

Vedder Price on

On June 9, 2025, Oregon Governor Tina Kotek signed into law Senate Bill 951 (the “2025 Act”). Unlike California’s AB 3129, which was vetoed by California Governor Gavin Newsom in September 2024, the passage of the 2025 Act...more

Goodwin

Oregon Governor Signs Law Aggressively Restricting Private Equity Investment in Medical Practices

Goodwin on

*UPDATE* Oregon Senate Bill 951, described in the alert below originally published on May 30, 2025, was signed into law by Oregon Governor Tina Kotek on Monday, June 9, and will apply to all new investments beginning January...more

Proskauer - Health Care Law Brief

Oregon Governor Signs S.B. 951, Representing the Nation’s Most Onerous Restriction on the Friendly PC Model

Over the past 3 years, as chronicled in several Proskauer alerts, an increasing number of states have sought to regulate physician practice management (“PPM”) and private equity transactions in the health care sector,...more

Akin Gump Strauss Hauer & Feld LLP

The First 100 Days of the New HSR Rules: Assessing the Impact

The new Hart-Scott-Rodino (HSR) requirements went into effect on February 10, 2025, meaning that May 21, 2025 marked their 100th day in effect. Here are just a few of our observations from the first 100 days of the new HSR...more

Greenbaum, Rowe, Smith & Davis LLP

Legal Risks and Challenges for Private Equity in Healthcare Acquisitions

Private Equity (PE) firms continue to be significant players in U.S. healthcare, acquiring assets across various sectors such as physician practices, home health, behavioral health, and urgent care. However, recent legal...more

Holland & Knight LLP

Podcast - Navigating the New Landscape of Private Equity in Healthcare

Holland & Knight LLP on

In this episode of "Counsel That Cares," Arjan Peters from Capstone moderates a conversation with his colleague Grace Totman, Holland & Knight healthcare attorney John Saran and Association for Responsible Healthcare...more

K&L Gates LLP

Private Equity in Australia: Upcoming Mandatory Merger Laws and Foreign Investment Changes

K&L Gates LLP on

WHAT’S ON THE AUSTRALIAN REGULATORY HORIZON? In this publication, we provide an overview of certain upcoming changes for private equity funds and their investors (both Australian and foreign) investing in Australia....more

Stevens & Lee

NY Department of Health Provides Guidance Regarding Material Transactions Law

Stevens & Lee on

Under the Material Transactions Law, certain health care entities involved in a transaction that increases gross, in-state revenue to at least $25 million must provide written notice of the transaction to the New York State...more

Morgan Lewis

M&A Considerations Across the Technology Sector

Morgan Lewis on

Technology is quickly becoming one of the most active and dynamic sectors for mergers and acquisitions (M&A) in 2025. Despite a macro environment filled with uncertainty, technology deal activity reflects an appetite for...more

Paul Hastings LLP

Check-Up and Diagnosis: The Ongoing Scrutiny of Private Equity Healthcare Investments

Paul Hastings LLP on

In 2024 alone, over 676 private equity firms and related investors acquired healthcare companies or related assets. The growing influence of private equity in the healthcare industry has not gone unnoticed on either of the...more

McGuireWoods LLP

A View From the Top: Jerin Johnson of Prime Providers

McGuireWoods LLP on

The interview below is part of a McGuireWoods series featuring interviews with C-suite leadership of private equity-backed portfolio companies....more

Goodwin

Five Trends Reshaping Pharmaceutical Manufacturing Partnerships

Goodwin on

How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities. The pharmaceutical manufacturing landscape is undergoing a profound shift, with...more

Bass, Berry & Sims PLC

Healthcare Trends & Transactions Q1 2025

Bass, Berry & Sims PLC on

The healthcare mergers and acquisitions (M&A) market began 2025 with a slower start than expected given the easing headwinds and building momentum at the end of last year, with the number of deals reported in Q1 lower than...more

76 Results
 / 
View per page
Page: of 4

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide